This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
The honest answer is that it depends, and here is what it depends on.
Answering the question post #30 raises rather than the one it answers.
Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
Whatever the answer on sequence verification turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
I will take the caveat as seriously as the claim, which is the point of putting it there.
Everything in post #34 holds. The case it does not cover is the one I have.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Filing a mild objection to the consensus on sequence verification. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Fragment compounds — where the material is part of a larger natural protein — should be identified by sequence rather than by name, because the naming in this space is inconsistent between suppliers.
Take the reasoning and check the arithmetic; I do not always get it right.
Post #36 answers the question as asked. The question underneath it is different.
Sequence verification: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Careful with the language on sequence verification. "Not detected" and "not present" are different findings and the first is a statement about the method.
Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.
The strength of my opinion here exceeds the strength of my evidence.
Sequence verification sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Post #43 describes the usual case. This is about the unusual one.
A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.
I am confident about the direction and much less about the magnitude.
Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.
Noted, and I have changed what I was going to do on the strength of it.
Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.
This follows post #50 rather than contradicting it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Second-hand, so weight it accordingly.
My experience of sequence verification contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
What I would want before treating sequence verification as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
No notes. Posting so the count is not one.
Picking up post #53: that is the part I would want checked first.
For any compound without a widely available reference standard, retention-time comparisons across laboratories are close to meaningless. Only a mass result travels.
Reading it again, the caveat matters more than the finding.
On sequence verification: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Adding a note of thanks rather than an opinion. I did not know most of that.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
It is worth stating the boring hypothesis before the interesting one.